Navigation Links
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Date:11/25/2008

SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the New York Palace Hotel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through December 17, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

SafeHarbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and onc
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , SHANGHAI, Nov. 30 /PRNewswire... pharmaceutical, biotechnology, and medical-device... operations in China and the United States,announ...nology Fast 50 China,2009 list for the fifth conse...owing companies in China,s technology, media, and ...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswir...rk, will initiate water-soluble carbon nanotube-ba...a. The water-soluble carbon nanotubes, which have ...jugation with cancer drugs, was developed in partn...The conjugated carbon nanotubes serves as a drug d...
(Date:11/25/2009)..., , BOSTON, Nov. 25 ...e H1N1 virus, genomic data from the 1918 pandemic ...the current H1N1 pandemic, today issued its latest...hows that the lethality of the H1N1 ("Swine Flu") ...during the virus,s current outbreak in the spring ...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...o 2013 ,, http://www.reportlinker.com/p016550...to-2013.html ,, Brazil Bioethanol Market Analy...e report provides detailed analysis and forecasts ...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10
..., Dec. 20 Conatus Pharmaceuticals Inc. today,anno...vel drug candidate,for the treatment of liver dise...ion in patients who have failed the approved stand... drug candidate, CTS-1027, is being studied as,a t...resulting from,infection by HCV. CTS-1027 inhibits...
... Calif., Dec. 20 Ardea Biosciences,Inc. (Nasdaq: ...velopment of,small-molecule therapeutics for the t...y diseases, today announced that it has entered in...stitutional investors to raise,approximately $40 m... 3.0,million newly issued shares of its common sto...
..., Dec. 20 /Xinhua-PRNewswire-FirstCall/ -- China T...TDC, "the Company" or "CTDC"), a,provider of clean...ing on,solar energy business in China, today annou...ategic plan to focus the Company,s management and,...olar energy., On December 18, 2007, the Company d...
Other Biology Technology:Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis 2Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3CTDC Announces the Disposal of Non-core Business 2
(Date:11/30/2009)...erimental Biology are pleased to announce that Dr...e Scientifique (CNRS) in the Universit de Nice-Sop...utstanding Paper Prize. ,The prize is awarded in r...tended to encourage young scientists, says Hans H... ,we truly appreciate when authors submit their ve...
(Date:11/30/2009)... rise scientists are presented with the complex ch...dapt. In a paper published in Insect Conservation...d Dr Miguel Rodriguez assess this challenge. , T....6˚C has already affected the Earth,s biota a...volutionary biologists is to predict how biologica...
(Date:11/30/2009)...seeing your extended family over the holidays was ...in the December 2009 print issue of the Journal o...hows that you might be right. Here,s the good news...ly new treatments that help keep autoimmune diseas.... That,s because researchers from the University o...
Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4How can scientists measure evolutionary responses to climate change? 2Seeing family for the holidays? Scientists discover how the stress might kill you 2Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 58522 1Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 58522 2Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 1Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 2Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6
...en oxides produced by huge fires and fossil fuel c...They are the primary ingredients in ground-level o...tation. , But new research led by a University of ...me regions, nitrogen oxides emitted by the soil ar...tantially larger role in seasonal air pollution th...
...circulates in our bodies through a complex network...his network is, however, of major importance for t...ur body. Researchers from the Flanders Interuniver...ith the Catholic University of Leuven, are the fir...th the help of tadpoles. This accelerates research...
...ie Mellon CyLab computer scientist Yang Cai is wor...e (ESTO), the Goddard Space Flight Center (GSFC) a...tion (NOAA) to develop new software for detecting ...aters. , "We are developing software that will mon...lies for public health," said Cai, who noted other...
Other Biology News:Study uncovers dirty little secret: Soil emissions are much-bigger-than-expected component of air pollution 2Study uncovers dirty little secret: Soil emissions are much-bigger-than-expected component of air pollution 3Tadpole soon to help in the fight against cancer and lymphedema 2Tadpole soon to help in the fight against cancer and lymphedema 3Carnegie Mellon cyLab researchers work to develop new red tide monitoring 2
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
...me isolated from Pseudomonas atlantica. Gelzyme en...producing carbohydrate molecules that can no longe...ot interfere with subsequent DNA manipulation. DNA...riction endonuclease digestions ligations and tran...
... contains the cellular components necessary for pr...tiation, elongation and termination factors) but h...reated Lysate is used primarily for the isolation ...ndogenous globin mRNA. Untreated Lysate is prepare...
Axl, phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Biology Products: